Sandra Rost

TL;DR: Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.

TL;DR: A diagnostic assay that measures programmed-death ligand 1 (PD-L1) expression, via immunohistochemistry, to identify patients who will derive the most benefit from treatment with atezolizumab, a humanized monoclonal anti-PD- L1 antibody is described.

TL;DR: The current knowledge of mechanisms of MET activation, the status of the clinical evaluation of MET‐targeted therapies, the associated efforts to identify and validate biomarkers, and the considerations and challenges for potential development of companion diagnostics are discussed.

TL;DR: Using HER2 as a model, data show MIBI analysis can quantitate protein expression with greater sensitivity and objectivity compared to standard pathologist interpretation, demonstrating its potential as a technology capable of advancing cancer and patient diagnostics.

TL;DR: A review of the technical features, advantages, and limitations of currently available multiplexed immunohistochemistry and spatial transcriptomic platforms can be found in this paper, with a focus on RNA and protein expression profiles in the same sample.